Paramita Sen
Overview
Explore the profile of Paramita Sen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duan J, Gajewski B, Sen P, Wick J
J Biopharm Stat
. 2023 Apr;
34(2):276-295.
PMID: 37016726
Detection of safety signals based on multiple comparisons of adverse events (AEs) between two treatments in a clinical trial involves evaluations requiring multiplicity adjustment. A Bayesian hierarchical mixture model is...
2.
Cho B, Kim D, Batra U, Park K, Kim S, Yang C, et al.
Cancer Res Treat
. 2022 Mar;
55(1):83-93.
PMID: 35344649
Purpose: Previous report from the ASCEND-8 trial showed consistent efficacy with less gastrointestinal (GI) toxicity in patients with anaplastic lymphoma kinase-rearranged (ALK+) advanced/metastatic non-small cell lung cancer (NSCLC) treated with...
3.
Tan D, Geater S, Yu C, Tsai C, Hsia T, Chen J, et al.
JTO Clin Res Rep
. 2021 Sep;
2(3):100131.
PMID: 34589995
Introduction: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients with advanced rearranged...
4.
Soria J, Tan D, Chiari R, Wu Y, Paz-Ares L, Wolf J, et al.
Lancet
. 2017 Jan;
389(10072):917-929.
PMID: 28126333
Background: The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based...
5.
Milowsky M, Dittrich C, Duran I, Jagdev S, Millard F, Sweeney C, et al.
Eur J Cancer
. 2014 Dec;
50(18):3145-52.
PMID: 25457633
Background: Second-line treatment options for patients with advanced urothelial carcinoma (UC) are limited. Fibroblast growth factor receptor 3 (FGFR3) is dysregulated in UC by activating mutations or protein overexpression in...
6.
Angevin E, Lopez-Martin J, Lin C, Gschwend J, Harzstark A, Castellano D, et al.
Clin Cancer Res
. 2013 Jan;
19(5):1257-68.
PMID: 23339124
Purpose: Signaling through the fibroblast growth factor (FGF) pathway may account for tumor resistance to antiangiogenic therapies targeting the VEGF pathway. Here, dovitinib (TKI258), a potent oral inhibitor of FGF...
7.
Akbar M, Chatterjee N, Sen P, Debnath A, Pal A, Bera T, et al.
Mol Biochem Parasitol
. 2003 Dec;
133(2):187-96.
PMID: 14698431
Entamoeba histolytica, although a microaerophilic protozoan parasite, encounters a high-oxygen environment, during invasive amoebiasis. The parasite requires specific regulation of certain proteins to maintain its physiological functions to survive in...